Kornimate/medical-research-clean huggingface dataset:
tempus crc surveillance study: a ctdna biomarker profiling study of patients with crc using ngs assays

Conditions: Colorectal Cancer

Summary: the study is an observational multicenter evaluation of participants with colorectal cancer (crc) who will receive longitudinal plasma ctdna biomarker profiling in addition to their standard-of-care therapy and disease surveillance.


Eligibility criteria:
inclusion criteria: * known or suspected colorectal adenocarcinoma (stage i to iva disease) * planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent. * 18 years old or older * willing and able to provide informed consent * willing to have additional blood samples collected during routine surveillance visits exclusion criteria: * not willing to have additional blood samples collected * pathology that is not consistent with colorectal adenocarcinoma

Keywords: cancer oncology observational genomic profiling precision medicine crc colorectal cancer ngs biomarkers
effectiveness and safety of distal left transradial access in coronary procedures.

Conditions: Cardiovascular Diseases; Cardiomyopathies

Summary: to evaluate the effectiveness and safety of distal left radial (dlr) access in coronary procedures at a tertiary center in trinidad and tobago.

an observational, retrospective study will be carried out. roughly 111 patients were registered at ewmsc and cardiac angiograms were done via approached through the left radial access between january 2020 and june 2021 at ewmsc. however since 2021 cardiac angiograms were also done via the anatomical snuff box. this study seeks to compare the results of cardiac angiograms vs left radial access and the anatomical snuff box.

Eligibility criteria:
cardiologist recommended guidelines.

Keywords: distal radial artery angiogram anatomical snuff box angiogram
the effects of music therapy on women's anxiety before and during cesarean delivery

Conditions: Pregnancy; Cesarean Section

Summary: the purpose of the study is to determine if listening to your choice of music with a portable mp3 player before and after a cesarean section for delivery of a baby will decrease the patient's anxiety level.

music has been suggested and evaluated as a therapeutic intervention to reduce preoperative anxiety for surgical patients. music intervention in the immediate preoperative period may be effective in lowering anxiety levels during cesarean delivery. if this investigation shows that music intervention before and after cesarean delivery reduces anxiety levels, this intervention can be integrated into future operative care for women having scheduled or emergency cesarean deliveries. music therapy could be expanded to included patients undergoing other surgical procedures under regional anesthesia. the effect of reducing anxiety levels could aid in lactation initiation and improve infant bonding in new mothers, but it could also shorten postoperative recovery time for all surgical patients.

Eligibility criteria:
inclusion criteria:women age 18 and older with a history of one prior cesarean delivery that are scheduled for a repeat cesarean delivery under regional anesthesia, or women who are undergoing a primary cesarean section will be eligible to participate. - exclusion criteria:women with cardiovascular disease, chronic hypertension, insulin dependent diabetes mellitus, multiple gestation pregnancies, psychiatric disorders, and fetal anomaly. -

Keywords: pregnancy cesarean section
effect of total intravenous anesthesia and balanced anesthesia on postoperative lung function

Conditions: Lung Function

Summary: the aim of the study is to investigate the effects of total intravenous anesthesia (tiva; propofol, remifentanil) and balanced anesthesia (bal; induction with propofol and fentanyl; maintenance of anesthesia with sevoflurane and nitrous oxide) on pulmonary function 30 minutes after emergence from the general anesthesia.


Eligibility criteria:
inclusion criteria: * asa 1-2 * bmi normal exclusion criteria: * lung disease * nicotine abuse

Keywords: forced vital capacity forced expired volume in 1 s
icotinib combined with whole brain radiotherapy in treating multiple brain metastases from non-small cell lung cancer

Conditions: Lung Cancer; Metastatic Cancer

Summary: the aim of this study is to explore the efficacy and toxicity of icotinib combined with wbrt in treating patients with multiple brain metastases from nsclc.

brain metastases occur in 25-40% of patients with non-small cell lung cancer (nsclc). it is one of the primary reasons resulting in treatment failure and the death. whole-brain radiation therapy (wbrt) is the standard approach to the treatment of multiple brain metastases from nsclc. regardless of the treatment of brain metastases by wbrt combined with systemic chemotherapy,outcomes of nsclc with brain metastases are still very poor. epidermal growth factor receptor tyrosine kinase inhibitors (egfr-tkis) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from nsclc. icotinib shows nearly the same effect as gefitinib in advanced nsclc patients failed with chemotherapy.

Eligibility criteria:
inclusion criteria: * cytologic or histological diagnosis of non-small cell lung cancer * patients with disease progression after systemic chemotherapy with two-drug combination regimens that includes a platinum agent or patients with egfr mutation status who have not been treated * patients are diagnosed with multiple brain metastases for the first time in 4 weeks * diagnosis of brain metastases is made based on magnetic resonance imaging (mri). * doctors consider the patient will benefit from wbrt * no prior brain radiotherapy * ecog performance status 0-2 * age:18-75 years * neutrophil count ≥1.5×10 to the 9th power/l and platelets≥100×10 to the 9th power/l. hemoglobin ≥90 g/l * hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (uln) alanine transaminase (alt) and aspartate transaminase (ast) less than or equal to 2.5 times uln (or less than or equal to 5 times uln in case of known liver involvement) * renal: serum creatinine less than or equal to 1.5 times upper limit of normal (uln) * patients with measurable brain metastases according to the response evaluation criteria in solid tumors (recist) criteria * patients must sign an informed consent indicating that they are aware of the investigational nature of the study exclusion criteria: * prior brain radiation therapy * solitary brain metastasis according to magnetic resonance imaging (mri) * mort than 3 extracranial organs have metastatic lesions * prior invasive malignancy (skin basal cell cancer, carcinoma in situ of cervix are permissible). * pregnant or breast feeding women

Keywords: tumors metastatic to brain non-small cell lung cancer icotinib
study evaluating the safety of hki-272 (neratinib) in subjects with advanced non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms

Summary: the purpose of this study is to learn whether hki-272 is safe and effective in treating non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * pathologic diagnosis of nsclc and current stage iiib (with pleural effusion) or iv, not curable with conventional therapy. for arm c, less than or equal to 20 pack-years smoking history and current non smoker. a pack year = number of packs of cigarettes smoked per day x years smoked. * progression following at least 12 weeks of treatment with tarceva or iressa. (arms a and b only) * ecog (eastern cooperative oncology group) performance status of 0, 1, or 2 (not declining within past 2 weeks). * tumor sample available and adequate for analysis. * at least one measurable target lesion. * adequate cardiac, kidney, and liver function * adequate blood counts exclusion criteria: * more than 3 prior cytotoxic chemotherapy treatments for relapsed or metastatic disease. * significant cardiac disease or dysfunction. * prior treatment with anthracyclines with cumulative dose of \>400 mg/m\^2. * active central nervous system metastases, as indicated by clinical symptoms and/or progressive growth. * use of tarceva or iressa within 14 days of treatment day 1 (arms a and b only). * major surgery, chemotherapy, radiotherapy, investigational drugs, or other cancer therapy within 3 weeks of treatment day 1. * significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom. * inability or unwillingness to swallow hki-272 capsules. * pregnant or breastfeeding women.

Keywords: lung cancer hki-272 neratinib nerlynx
assessment of competence in colonoscopy using motion capture

Conditions: Sensitivity Training Groups

Summary: aim: to study the basic technical skills of colonoscopy using a ms kinect for motion analysis. in order to develop a non-biased tool to monitor competence.

to compare a group of novices to a group of experienced endoscopists performining colonoscopy. analyzing the motion pattern of the performers using a kinect. use the contrasting group method to set standards.

Eligibility criteria:
inclusion criteria: none experience in colonoscopy or experience more than 350 colonoscopy procedures - exclusion criteria: none -

Keywords: simulation training colonoscopy standard setting
endovascular treatment in ischemic stroke follow-up evaluation

Conditions: Stroke, Acute

Summary: study like register with biomarkers samples for patient experiencing acute ischemic stroke, to assess clinical outcomes and different factors that may affect the clinical outcomes.


Eligibility criteria:
inclusion criteria: * age 18 and older (i.e., candidates must have had their 18th birthday) * neuroimaging demonstrates acute ischemic stroke with large vessel proximal with the use of neuro-thrombectomy devices intended to restore blood flow * no upper or lower limits of the neurological severity at baseline (nihss). * with or without intravenous thrombolysis * oral informed consent (patient and/or trustworthy person) non-inclusion criteria: * pregnant or breast-feeding women * patient benefiting from a legal protection * non-membership of a national insurance scheme
clinical trial readiness for the dystroglycanopathies

Conditions: Muscular Dystrophy

Summary: the purpose of the study is to describe the early signs and symptoms of the dystroglycanopathies, and to gather information that will be required for future clinical trials.

muscular dystrophies are a diverse group of inherited disorders characterized by progressive muscle weakness and wasting. the disorders are caused by mutations, or changes, in genes. genes are tiny pieces of inherited material (dna) that direct the body to make certain kinds of proteins. in this study, researchers will examine the clinical presentation of muscular dystrophy caused by abnormal glycosylation of alpha-dystroglycan. patients with dystroglycanopathies could have mutations in any one of the more than 20 currently identified genes, or evidence of dystroglycanopathy in biopsied muscle tissue . symptoms range from congenital muscular dystrophy that may involve the brain and eye, through an adult-onset limb girdle muscular dystrophy. the study involves a clinical evaluation at the university of iowa. the evaluation includes muscle strength and motor ability testing, lung function testing, quality of life and activity assessment, and a review of past medical history. portions of this evaluation will be repeated on a yearly basis. financial assistance is available for travel to iowa city. support is also available for genetic testing for people with a dystroglycanopathy diagnosis based on muscle or skin biopsy analysis. knowledge gained from this study will improve healthcare recommendations for people with dystroglycanopathies, and provide a baseline for further study, including potential treatment options.

Eligibility criteria:
inclusion criteria: * elevated ck (creatine kinase) * evidence of a dystroglycanopathy as determined by review of muscle pathology or documented mutation in one of the known genes or abnormal alpha-dystroglycan glycosylation in cultured fibroblasts * dystroglycanopathies are predicted to affect all racial and ethnic backgrounds, and all patients with dystroglycanopathies will be eligible for participation. * participants may be of any age, including children, and males and females will be recruited equally. * patients will have varying degrees of muscular weakness, but otherwise should be in relatively good health. exclusion criteria: * there are no exclusion criteria.

Keywords: muscular dystrophy md fukutin-related protein gene limb girdle fkrp gene congenital muscular dystrophy childhood onset lgmd adult onset lgmd pomt1 pomt2 pomgnt1 large alpha dystroglycan dystroglycanopathy ispd/crppa dpm 1, 2 or 3 gmppb b3gnt1/b4gat1 b3galnt2 gtdc2/pomgnt2 tmem5/rxylt1 fukutin dag1 pomk/sgk196 dolk go5r2 trappc11
fecal microbiotatransplant for the treatment of parkinson's disease

Conditions: Parkinson Disease

Summary: fmt may significantly improve quality of life and parkinson disease (pd) symptom severity measurements. we hypothesize that gut microbial dysbiosis is a major contributing factor in parkinson's disease.

this is an open-label clinical trial to evaluate the safety of fecal microbiota transplant following a 10 day treatment with vancomycin in adult subjects with parkinson's disease. subjects in the study are required to meet with the study clinician on 11 occasions: two (2) visits for informed consent and baseline assessment, one (1) visit prior to fmt for colonoscopy instructions and exam, one (1) visit for the fecal microbiota transplant procedure by colonoscopy at an outpatient surgical center, seven (7) visits for post-fmt assessment. there are also daily phone calls in the week following the fmt, and weekly phone call visits (during weeks in which there is not a physical visit) to check up on how the subject is doing, any change in medications, side effects, and answer any questions.

Eligibility criteria:
inclusion criteria: * individuals diagnosed with pd exclusion criteria: * non-pd individuals
circulating exosome rna in lung metastases of primary high-grade osteosarcoma

Conditions: Lung Metastases; Osteosarcoma

Summary: the purpose of this study is to learn whether the profile of rna from circulating exosomes can be used as a biomarker for lung metastases of primary high-grade osteosarcoma. circulating exosomes plays roles in metastases in many kinds of cancer including osteosarcoma. by rna profiling researchers may find lung metastases earlier than conventional work-up and predict the oncological outcomes.

investigators have performed a 4 patients pilot study under the oversight of hospital's ethics committee, and investigator found that the levels and mutations of circulating exosome rna from patients with or without lung metastasis have significant differences. then investigators wish to register this study to do a further research, in order to reveal the roles of circulating exosome rna in metastases of osteosarcoma.

Eligibility criteria:
inclusion criteria: * diagnosis by biopsy: primary high-grade osteosarcoma, including conventional osteosarcoma, telangiectatic osteosarcoma, small cell osteosarcoma, high-grade surface osteosarcoma. * tumor located in the extremities or pelvis. * age 12-60 years. * no prior history of cancer and no prior treatment elsewhere. * no prior history of chronic diseases including autoimmune disease, chronic infection, etc. which may interfere the level of circulating exosomes. exclusion criteria: * initial misdiagnosis confirmed by specimen of definitive surgery. * applying target drugs in the period of treatment which may reduce tumor derived exosomes * withdraw from the study for any reason

Keywords: rna profiling exosome lung metastases osteosarcoma
study to evaluate the effect of a probiotic in covid-19

Conditions: COVID-19; Coronavirus Infection

Summary: a prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients with negative pcr after infection with the coronavirus sars-cov-2.

in this study, the investigators hypothesize a positive effect of probiotic on the gut microbiome that could led to produce a less severe clinical evolution of the disease.

Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of sars-cov.2 infection using the pcr and that require admission to the hospitalization area. exclusion criteria: * inability or refusal to sign informed consent. * allergy or intolerance to the intervention product or its components.

Keywords: probiotic
substance use screening and prevention for adolescents in pediatric primary care

Conditions: Substance Use

Summary: this study is to test the effectiveness of integrating and adapting two national institute on drug abuse (nida)-funded procedures for use in primary care pediatric clinics serving low-income youth: 1)the youth risk index (yri) and transmissible liability index-parent (tli-p) nurse and/or research assistant-administered screening tools for high risk of substance use (su) prior to high school and thus also for sud and 2) the family check-up (fcu) - a brief, family-based program to prevent su/sud with replicated efficacy.

this study is to test the effectiveness of integrating and adapting two national institute on drug abuse (nida)-funded procedures for use in primary care pediatric clinics serving low-income youth: 1) the youth risk index (yri) and transmissible liability index (tli-p) nurse and/or research assistant-administered screening tools for high risk of substance use (su) prior to high school and thus also for sud and 2) the family check-up (fcu) - a brief, family-based program to prevent su/sud with replicated efficacy. the following three aims focus on evaluating and refining the adaptation of the yri \& tli-p program for primary-care use: 1) to replicate the effectiveness of the yri \& tli-p screening tool in terms of concurrent and predictive validity and the engagement rate in the fcu; 2) to identify and address challenges in implementing and integrating the yri \& tli-p/fcu prevention strategy within a primary care clinic serving urban, low-income youth; and 3) to test the effectiveness of the yri \& tli-p/fcu on emerging su, sexual activity, and conduct problems, as well as the putative mediators of these outcomes including parenting and parental well-being. based on prior fcu efficacy studies, 500 dyads of parents and their 9 years, 9 months to 13 years, 11 months old children from low-income, ethnically diverse families will be recruited from two large primary care clinics in an urban community. the fcu will be delivered for two or three years to test impact of dosage. participants will be followed-up one year after completing fcu to evaluate longitudinal outcomes of the integrated yri \& tli-p/fcu .

Eligibility criteria:
inclusion criteria: * child aged 9 years, 9 months to 13 years, 11 months. * a biological or adoptive parents or legal guardian with appropriate documentation with custody of the child. * either child or parent's score on screening assessment score must fall in elevated risk range. * child must be recipient of needs based medicaid or family income must be at or below 150% health and human services (hhs) poverty guidelines. exclusion criteria: * inability to read english, * having moderate to severe mental disability (based on medical records), * child not accompanied by a biological or adoptive parent with legal custody or legal guardian with appropriate documentation * participant in the early steps project

Keywords: substance use
a prospective study to compare bupivacaine and exparel versus bupivacaine or exparel alone for postoperative pain relief

Conditions: Low Back Pain; Lumbosacral Radiculopathy; Lumbar Disc Degeneration; Lumbar Disc Herniation; Stenosis; Spondylolisthesis; Spondylolysis; Deformity of Spine

Summary: the purpose of this study is to collect information about how patients feel when doctors manage their pain after lumbar spine surgery using a combination of exparel® and bupivacaine injected into the lumbar spine at the end of surgery, compared to the patients that doctors use only exparel® or bupivacaine to manage their pain. this information will help doctors determine which approach works best for patients who will receive surgery in their lumbar spine in the future.


Eligibility criteria:
inclusion criteria: 1. age 18 or older; 2. primary indication is low back pain, lumbosacral radiculopathy, lumbar disc degeneration, lumbar disc herniation, stenosis, spondylolisthesis, spondylolysis, or deformity requiring surgical intervention; 3. scheduled to undergo primary, 1 or 2 level, posterior lumbar laminectomy with or without fusion, discectomy with fusion, or fusion at virtua memorial hospital; 4. willing to provide informed consent, participate in study, and comply with study protocol. exclusion criteria: 1. hypersensitivity or allergy to local anesthetics; 2. pregnant or contemplating pregnancy prior to surgery; 3. previous surgery in lumbar spine (i.e. other than microdiscectomy); 4. prior treatment for alcohol, recreational drug, or opioid abuse; 5. serious spinal conditions (e.g. spinal cord compression, cauda equina syndrome, spinal infection, spinal tumor, spinal fracture, inflammatory or systemic spinal arthritis); 6. surgery involving more than 2 vertebral levels; 7. worker's compensation or personal injury related to lumbar spine (treatment outcomes may be affected by patient's personal interests \[21\]; could also run into potential issues with reimbursement). 8. lactating women 9. patients with end stage liver disease
integrative psychosocial group treatment

Conditions: Chronic Pain; Opioid Misuse

Summary: a fundamental challenge for healthcare is to achieve a balance between decreasing the misuse of opioids and associated harms while optimizing patient care, including the provision of multidisciplinary treatments for chronic pain. however, despite recommendations that non-pharmacological interventions are rudimentary in the management of chronic pain, the literature describing which psychosocial interventions are best practice is nearly non-existent. most of the psychosocial treatments that target either cncp or opioid misuse are very general and broad-based therapies. however, there is a lack of evidence-informed direction guiding which psychosocial treatments should be adapted to this specialized population and thus, further research is needed.

this project is a pilot randomized controlled trial (rct) of an integrated psychosocial group treatment (ipgt) in patients with chronic pain who are at risk for opioid misuse. ipgt is a comprehensive approach that blends evidenced-based psychosocial treatments for chronic pain and opioid misuse and addresses each issue individually, but also the interconnections between the overlapping problems. ipgt consists of 6 weekly group sessions of motivational interviewing and behavioral change, self-management, and pain education focused on appropriate adherence to treatment and resisting urges to misuse prescription medications. the intervention also entails an education session on knowledge pertaining to overdose and naloxone distribution. this study will involve the randomization of 40 patients to receive either: (1) treatment as usual (tau; n=20); or (2) integrated psychosocial group intervention (ipgt; n=20). this study will: (1) establish feasibility; (2) demonstrate acceptability; and (3) demonstrate preliminary efficacy for an integrated psychosocial group treatment model for patients with chronic pain who are at risk of opioid misuse. the data generated from this study will also serve as a foundation for future implementation to support a subsequent fully-powered rct.

Eligibility criteria:
inclusion criteria: * adults (≥18 years) * chronic pain (3 months or longer) * at risk for opioid misuse exclusion criteria: * non-english speaking * cannot attend group sessions

Keywords: behavioral intervention medication adherence psychosocial treatment